Phase II multi-institutional trial of the histone deacetylase inhibitor romidepsin as monotherapy for patients with cutaneous T-cell lymphoma.

By R. Piekarz, R. Frye, M. Turner, J. Wright, S. L. Allen, M. Kirschbaum, J. Zain, H. Prince, J. Leonard, L. Geskin and 10 more. Journal of Clinical Oncology, 2009

712 citations recorded by the source corpus.

Subfields: Immunology, Molecular Biology

View Paper: https://www.semanticscholar.org/paper/f3af600ef9aba4b3522071e03ed760fd0907e972

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Molecular Biology

Citations in the corpus

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents (2015, methodology): “The second HDAC inhibitor approved for the treatment of CTCL was based on two large phase II studies: a multi-institutional study based at the NCI in the US (71 patients), and an international study (96 patients) [27,28].”
Microtubule-binding agents: a dynamic field of cancer therapeutics (2010, background): “Romidepsin , a dolastatin 15 analogue, which also possesses activity as a histone deacetylase inhibitor, was recently discovered to be active in cutaneous T cell lymphoma with a 34% objective response rat”
New and emerging HDAC inhibitors for cancer treatment. (2014, neutral): “The most successful clinical application of HDACis has been the use of vorinostat and romidepsin against refractory cutaneous and peripheral T cell lymphoma (52–55).”
Cancer epigenetics: from mechanism to therapy. (2012, background): “Based on impressive preclinical and clinical data, two pan-HDAC inhibitors, Vorinostat and Romidepsin, have recently been granted FDA approval (Olsen et al., 2007; Piekarz et al., 2009) for clinical use in patients with cutaneous T cell lymphoma (Figure 1).”
Romidepsin in the treatment of cutaneous T-cell lymphoma (2011, neutral): “31,36 Most of these adverse events were mild (grade 1 or 2).”
Cancer epigenetics reaches mainstream oncology (2011, neutral): “To date, four have been approved by the US Food and Drug Administration (FDA) for cancer treatment: two DNMT inhibitors, vidaza and decitabine (5-aza- and 5-aza-2′-deoxycytidine, respectively), for patients with myelodysplastic syndrome who have few therapeutic options and develop acute leukemia; an”